UBS maintains Axsome Therapeutics at Buy, lowers price target to $239 from $256
UBS kept its Buy rating on Axsome Therapeutics but reduced its price target to $239 from $256, a 6.6% cut. The new target suggests a 75.7% upside from the Nov 2 close of $136.01. Recent analyst price targets for the company range from $220 to $273.
How this was made
The 30-second read
Why it matters
A lower price target can influence short-term positioning and options pricing, but the lack of new company-specific information limits fundamental repricing.
Market read
Traders may adjust expectations for AXSM’s valuation and monitor whether other analysts follow with similar target cuts or rating changes.
What to watch
Without the underlying thesis for the target reduction, traders may overreact; subsequent analyst notes or company-specific catalysts (trial/regulatory/commercial updates) would likely dominate.
Background
The piece is a sell-side update summarizing UBS’s stance on Axsome Therapeutics, including a revised price target and a range of recent analyst targets.
Ticker impact
UBS maintained Axsome Therapeutics at Buy and cut its price target to $239 from $256, signaling a valuation reset despite the Buy rating.
Likely mild downside or capped upside as traders price in the lower target while watching for follow-on analyst changes.
This is an analyst note update (rating maintained, target lowered). The article provides no new company fundamentals, so impact should be sentiment-driven rather than fundamental.
Market effects
Limited read-through to the broader biotech/neurology space because the article contains no new clinical, regulatory, or commercial datapoints.
Minimal, as this is a single-name analyst target adjustment.
Low, since it does not reference cross-market policy, supply, or global deal activity.
Counterpoint
The maintained Buy rating could be interpreted as UBS still sees favorable risk-reward, so the target cut may reflect valuation conservatism rather than deteriorating fundamentals.
Key entities
- companyAxsome Therapeutics
Subject of the analyst action, with UBS maintaining Buy and lowering the price target to $239.
